TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Diagnosis of aplastic anemia, with refractory thrombocytopenia following at least one treatment course of horse or rabbit ATG/cyclosporine.~ 2. Platelet count less than or equal to 30,000/microL~ 3. Age greater than or equal to 12 years old~EXCLUSION CRITERIA:~1. Diagnosis of Fanconi anemia~2. Infection not adequately responding to appropriate therapy~3. Patients with a PNH clone size in neutrophils of greater than or equal to 50%~4. HIV positivity~5. Creatinine \> 2.5~6. Bilirubin \> 2.0~7. SGOT or SGPT \> 5 times the upper limit of normal~8. Hypersensitivity to eltrombopag or its components~9. Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~10. History of malignancy other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (for instance squamous cell or other skin cancers, stage 1 breast cancer, cervical carcinoma in situ, etc)~11. Unable to understand the investigational nature of the study or give informed consent~12. History of congestive heart failure arrhythmia requiring chronic treatment, arterial or venous thrombosis (not excluding line thrombosis) within the last 1 year, or myocardial infarction within 3 months before enrollment~13. ECOG Performance Status of 3 or greater~14. Treatment with horse or rabbit ATG or Campath within 6 months of study entry. Concurrent stable treatment with cyclosporine or G-CSF is permitted.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography~* No signs or symptoms of congestive heart failure and who have not been hospitalized for heart failure~Exclusion criteria:~* Myocardial Infarction (MI) within 3 months of screening~* Unstable angina within 14 days of screening, or any evidence of myocardial ischemia~* Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis~* Severe congenital heart diseases~* Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening~* Second or third degree heart block without a permanent cardiac pacemaker~* Stroke within 3 months of screening, or other evidence of significantly compromised central nervous system (CNS) perfusion~* Total bilirubin of \> 1.5 mg/dL or other liver enzymes \> 1.5 times the upper limit of normal (mg/dL = milligrams per deciliter)~* Serum creatinine of \> 3.0 mg/dL~* Serum sodium of \< 125 mEq/dL or \> 160 mEq/dL (milliequivalents per deciliter)~* Serum potassium of \< 3.5 mEq/dL or \> 5.0/dL~* Serum digoxin level of \> 2.0 ng/ml (nanograms per milliliter)~* Systolic pressure of \< 85 mm Hg (millimeters of mercury)~* Hemoglobin \< 10 gm/dl (grams per deciliter)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BNP (nesiritide) (Type: ACTIVE_COMPARATOR): BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Online Trial Examining Validity of the Shared Decision Making Process Survey With Video Vignettes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Speak English~* No prior diagnosis of colorectal cancer~* No history of heart attack~* No history of stroke~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- High Cholesterol Good Video First (Type: EXPERIMENTAL): Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
- Colorectal Cancer Good Video First (Type: EXPERIMENTAL): Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
- High Cholesterol Poor Video First (Type: EXPERIMENTAL): Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
- Colorectal Cancer Poor Video First (Type: EXPERIMENTAL): Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born less than or equal to 30 weeks gestation or less than 1500 g at birth~Exclusion Criteria:~* Patients with liver disease as tested by liver function tests (LFTs)~* ≤ 500 grams birthweight

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Standard Nutrition) (Type: ACTIVE_COMPARATOR): Infants in this group will receive standard lipids (predominantly Omega-6 fatty acids).
- Omegaven (Type: EXPERIMENTAL): Infants in this group will receive lipid supplementation with omega-3 fatty acids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between age 18 and 70 years~* Active and stable plaque psoriasis with a BSA≥10 or PASI≥10.~Exclusion Criteria:~* Evidence of skin conditions other than psoriasis~* Psoralen plus psoralen + ultraviolet A (PUVA), ciclosporin, acitretin, alefacept, anakinra, or any other systemic anti-psoriasis therapy or disease-modifying antirheumatic drugs (DMARD) with 28 days of screening~* ultraviolet B (UVB) therapy, topical steroids, topical Vitamin A or D analog preparations, or anthralin~* Prior exposure to any TNF-inhibitor. Prior exposure to efalizumab~* Corticosteroid dose of prednisone \>10 mg/day~* Serious infection~* Receipt of any live vaccine~* Abnormal hematology or chemistry~* Body mass index (BMI) \> 38~* Pregnancy or Breastfeeding~* Significant concurrent medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: EXPERIMENTAL): Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
- placebo (Type: PLACEBO_COMPARATOR): Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable coronary artery disease (CAD) or acute coronary syndromes (ACS) following percutaneous coronary intervention (PCI)~Exclusion Criteria:~* abnormal platelet count in patients,~* severe liver disorders,~* current gastrointestinal disorders,~* current infections,~* congestive heart failure,~* known bleeding disorders,~* treatment with bivalirudin or glycoprotein IIb/IIIa antagonists within the last 7 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- aspirin, clopidogrel (Type: EXPERIMENTAL): If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ethiopia Malaria Therapeutic Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Slide-confirmed infection with P. falciparum, with parasitemia of 1,000-100,000 asexual forms/ μl or slide confirmed infection with P. vivax with \> 250 asexual forms/ μl~* Lives within 20 km of the enrolling health facility~* Weight ≥ 5.0 kg~* Axillary temperature ≥ 37.5º C or history of fever during the previous 24 or 48 hours for P. falciparum and P. vivax infection, respectively~* Patient or caregiver agrees to all blood draws and return visits.~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean (NCHS/WHO normalized reference values;~* Slide confirmed infection with any other Plasmodium spp. besides falciparum/vivax or mixed plasmodium infection~* Severe anemia, defined as Hg \< 5 g/dl~* Known hypersensitivity to any of the drugs being evaluated~* Presence of febrile conditions caused by diseases other than malaria~* Serious or chronic medical condition (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)~* Pregnant or breastfeeding women.~* Children weighing less than 5 kilograms.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroquine-P. vivax (Type: EXPERIMENTAL): P. vivax randomized to receive chloroquine 3-day regimen
- Artemether-Lumefantrine: P. vivax (Type: EXPERIMENTAL): None
- Artemether-lumefantrine: P. falciparum (Type: EXPERIMENTAL): administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving at least 11 infusions of natalizumab as disease-modifying monotherapy for RRMS that is consistent with the approved dosing~Exclusion Criteria:~* Patients for whom the NTZ infusion history and/or MRI and clinical history is not available.~* Patients with dosing gap defined as \>=12 weeks between any two doses.~* Patients with over dose defined as \<3 weeks between any two doses.~* Pregnancy during the follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Interval Dosing (SID) (Type: None): Patients continuing Natalizumab treatment with standard interval dosing defined as \> 11 infusions per year
- Extended Interval Dosing (EID) (Type: None): Patients switching to extended interval dosing defined as ≤ 10 infusions per year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TAO symptom duration less than 6 months~* Eyelid retraction or swelling~* Participants who is able to sign a consent agreement and proceed study~Exclusion Criteria:~* Previous steroid or radiation treatment for TAO~* Compressive optic neuropathy~* Suspicious of glaucoma or high risk of intraocular pressure elevation~* Patients with eyeball pain and/ or 4 or more of Mourtis' clinical activity score(CAS)~* Patients who are not in euthyroid status at the start of study period and or the whole duration of study period~* Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Triam inj (Type: EXPERIMENTAL): None
- observation group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of schizophrenia~* Patients in an acute psychotic episode requiring full hospitalization~Exclusion Criteria:~* Significant medical conditions (heart, kidney, liver, thyroid or neurological diseases, hypovitaminosis B12, hyponatremia)~* Pregnancy~* Breastfeeding~* Previous hypersensitivity to sodium nitroprusside~* DSM-IV diagnosis of drug abuse or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sodium nitroprusside (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Glucose solution 5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients, aged 10 years and above, with β-thalassemia major or DBA or sideroblastic anemia on chronic transfusion therapy, having given written consent to participate in the study.~* Patients with cardiac iron as measured by a myocardial T2\* value that is ≥ 6ms but not ≥ 20 ms.~* Patients with a lifetime history of at least 50 units of red cell transfusions, and must be receiving at least ≥10 units/yr of red blood cells transfusions.~* Patients with a left ventricular ejection fraction (LVEF) ≥ 56 % as determined by cardiovascular magnetic resonance (CMR).~* Patients with liver iron content (LIC) value ≥ 3 mg Fe / g dw, as determined by liver MRI.~Exclusion criteria:~* Patients with clinical symptoms of cardiac dysfunction.~* Patients unable to undergo study assessments including MRI~* Patients participating in another clinical trial or receiving an investigational drug.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): 20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
- Deferasirox Placebo (Type: ACTIVE_COMPARATOR): 50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
- Extension: deferoxamine to deferasirox (Type: EXPERIMENTAL): DFO to ICL (patients who switched from DFO to deferasirox in extension)
- Extension: deferasirox to deferoxamine (Type: EXPERIMENTAL): ICL to DFO (patients who switched from deferasirox to DFO in extension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~children with or without a diagnosis of ASD between 18 to 71 months of age~Exclusion Criteria:~native language is not English born premature (\< 36 weeks) has uncorrected hearing or vision impairments has developmental disorders or medical conditions other than ASD that affect language or cognition (excepting psychiatric conditions often comorbid with ASD such as ADHD) has a history of photosensitive epileptic seizures

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- Addressed (Type: ACTIVE_COMPARATOR): Children participate via video in an interaction with an experimenter who uses the word to be learned.
- Overheard (Type: EXPERIMENTAL): Children watch via video while an experimenter uses the word to be learned in an interaction with another experimenter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection~* Chronic HCV infection~* Subject must be HCV treatment-naïve or have failed prior HCV treatment~* Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease~Exclusion Criteria:~* Positive test result at screening for Hepatitis B surface antigen or anti-human immunodeficiency virus (anti-HIV) antibody~* HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype~* Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-493/ABT-530

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete